Breathlin® SR is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste. Breathlin® SR Tablets in a controlled-release system allows a 24-hour dosing interval for appropriate patients. Breathlin® SR is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
Breathlin® SR (Theophylline® SR anhydrous tablet) is contraindicated in patients with a history of hypersensitivity to Breathlin® SR or other components in the product. Breathlin® SR should be administered carefully to children under 6 months of age.
•
Cost effective than other therapies
•
Unique SR formulation ensures less side-effects
•
Once daily anti-asthmatic ensures patient compliance
0 comments:
Post a Comment